Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 63

1.

Quantum chemical and experimental evaluation of the inhibitory action of two imidazole derivatives on mild steel corrosion in sulphuric acid medium.

Ouakki M, Galai M, Rbaa M, Abousalem AS, Lakhrissi B, Rifi EH, Cherkaoui M.

Heliyon. 2019 Nov 20;5(11):e02759. doi: 10.1016/j.heliyon.2019.e02759. eCollection 2019 Nov.

2.

Children vaccination coverage surveys: Impact of multiple sources of information and multiple contact attempts.

Kiely M, Boulianne N, Talbot D, Ouakki M, Guay M, Landry M, Sauvageau C, De Serres G.

Vaccine. 2019 Nov 20. pii: S0264-410X(19)31537-3. doi: 10.1016/j.vaccine.2019.11.014. [Epub ahead of print]

PMID:
31759736
3.

Priming effect of bivalent and quadrivalent vaccine for HPV 31/33/45/52: an exploratory analysis from two clinical trials.

Sauvageau C, Panicker G, Unger ER, De Serres G, Schiller J, Ouakki M, Gilca V.

Hum Vaccin Immunother. 2019 Oct 22:1-5. doi: 10.1080/21645515.2019.1669413. [Epub ahead of print]

PMID:
31545130
4.

Promoting vaccination in maternity wards ─ motivational interview technique reduces hesitancy and enhances intention to vaccinate, results from a multicentre non-controlled pre- and post-intervention RCT-nested study, Quebec, March 2014 to February 2015.

Gagneur A, Battista MC, Boucher FD, Tapiero B, Quach C, De Wals P, Lemaitre T, Farrands A, Boulianne N, Sauvageau C, Ouakki M, Gosselin V, Petit G, Jacques MC, Dubé È.

Euro Surveill. 2019 Sep;24(36). doi: 10.2807/1560-7917.ES.2019.24.36.1800641.

5.

Long intervals between two doses of HPV vaccines and magnitude of the immune response: a post hoc analysis of two clinical trials.

Gilca V, Sauvageau C, Panicker G, De Serres G, Schiller J, Ouakki M, Unger ER.

Hum Vaccin Immunother. 2019;15(7-8):1980-1985. doi: 10.1080/21645515.2019.1605278. Epub 2019 Jun 3.

PMID:
31017850
6.

Changes in vascular accesses and in incidence rates of dialysis-related bloodstream infections in Québec, Canada, 2011-2017.

Fortin É, Ouakki M, Tremblay C, Villeneuve J, Desmeules S, Parisien N, Moisan D, Frenette C; for SPIN-BAC-HD.

Infect Control Hosp Epidemiol. 2019 Jun;40(6):627-631. doi: 10.1017/ice.2019.65. Epub 2019 Apr 8.

PMID:
30957725
7.

Promoting vaccination in the province of Québec: the PromoVaQ randomized controlled trial protocol.

Gagneur A, Quach C, Boucher FD, Tapiero B, De Wals P, Farrands A, Lemaitre T, Boulianne N, Sauvageau C, Ouakki M, Gosselin V, Gagnon D, Petit G, Jacques MC, Dubé È.

BMC Public Health. 2019 Feb 6;19(1):160. doi: 10.1186/s12889-019-6468-z.

8.

Impact of vaccine delays at the 2, 4, 6 and 12 month visits on incomplete vaccination status by 24 months of age in Quebec, Canada.

Kiely M, Boulianne N, Talbot D, Ouakki M, Guay M, Landry M, Sauvageau C, De Serres G.

BMC Public Health. 2018 Dec 11;18(1):1364. doi: 10.1186/s12889-018-6235-6.

9.

Short-term safety of 4CMenB vaccine during a mass meningococcal B vaccination campaign in Quebec, Canada.

De Serres G, Billard MN, Gariépy MC, Rouleau I, Toth E, Landry M, Boulianne N, Gagné H, Gilca V, Deceuninck G, Ouakki M, Skowronski DM.

Vaccine. 2018 Dec 18;36(52):8039-8046. doi: 10.1016/j.vaccine.2018.10.095. Epub 2018 Nov 19.

PMID:
30467063
10.

Vaccination Against Influenza in Pregnancy: A Survey of Canadian Maternity Care Providers.

Dubé E, Gagnon D, Kaminsky K, Green CR, Ouakki M, Bettinger JA, Brousseau N, Castillo E, Crowcroft NS, Driedger SM, Greyson D, Fell D, Fisher W, Gagneur A, Guay M, Halperin D, Halperin SA, MacDonald S, Meyer SB, Waite NM, Wilson K, Witteman HO, Yudin M, Cook JL; Canadian Immunization Network.

J Obstet Gynaecol Can. 2019 Apr;41(4):479-488. doi: 10.1016/j.jogc.2018.09.007. Epub 2018 Nov 6.

PMID:
30409569
11.

Immunogenicity and safety of a mixed vaccination schedule with one dose of nonavalent and one dose of bivalent HPV vaccine versus two doses of nonavalent vaccine - A randomized clinical trial.

Gilca V, Sauvageau C, Panicker G, De Serres G, Ouakki M, Unger ER.

Vaccine. 2018 Nov 12;36(46):7017-7024. doi: 10.1016/j.vaccine.2018.09.057. Epub 2018 Oct 9.

12.

Antibody persistence after a single dose of quadrivalent HPV vaccine and the effect of a dose of nonavalent vaccine given 3-8 years later - an exploratory study.

Gilca V, Sauvageau C, Panicker G, De Serres G, Ouakki M, Unger ER.

Hum Vaccin Immunother. 2019;15(2):503-507. doi: 10.1080/21645515.2018.1522469. Epub 2018 Sep 27.

13.

Overview of knowledge, attitudes, beliefs, vaccine hesitancy and vaccine acceptance among mothers of infants in Quebec, Canada.

Dubé È, Farrands A, Lemaitre T, Boulianne N, Sauvageau C, Boucher FD, Tapiero B, Quach C, Ouakki M, Gosselin V, Gagnon D, De Wals P, Petit G, Jacques MC, Gagneur A.

Hum Vaccin Immunother. 2019;15(1):113-120. doi: 10.1080/21645515.2018.1509647. Epub 2018 Sep 11.

14.

Impact of the addition of new vaccines in the early childhood schedule on vaccine coverage by 24 months of age from 2006 to 2016 in Quebec, Canada.

Kiely M, Boulianne N, Talbot D, Ouakki M, Guay M, Landry M, Zafack J, Sauvageau C, De Serres G.

Vaccine. 2018 Jul 5;36(29):4383-4391. doi: 10.1016/j.vaccine.2018.03.085. Epub 2018 Jun 7.

PMID:
29887321
15.

Measuring vaccine acceptance among Canadian parents: A survey of the Canadian Immunization Research Network.

Dubé E, Gagnon D, Ouakki M, Bettinger JA, Witteman HO, MacDonald S, Fisher W, Saini V, Greyson D; Canadian Immunization Research Network.

Vaccine. 2018 Jan 25;36(4):545-552. doi: 10.1016/j.vaccine.2017.12.005. Epub 2017 Dec 9.

PMID:
29233605
16.

Understanding Vaccine Hesitancy in Canada: Results of a Consultation Study by the Canadian Immunization Research Network.

Dubé E, Gagnon D, Ouakki M, Bettinger JA, Guay M, Halperin S, Wilson K, Graham J, Witteman HO, MacDonald S, Fisher W, Monnais L, Tran D, Gagneur A, Guichon J, Saini V, Heffernan JM, Meyer S, Driedger SM, Greenberg J, MacDougall H; Canadian Immunization Research Network.

PLoS One. 2016 Jun 3;11(6):e0156118. doi: 10.1371/journal.pone.0156118. eCollection 2016.

17.

Paresthesia and sensory disturbances associated with 2009 pandemic vaccine receipt: Clinical features and risk factors.

De Serres G, Rouleau I, Skowronski DM, Ouakki M, Lacroix K, Bédard F, Toth E, Landry M, Dupré N.

Vaccine. 2015 Aug 26;33(36):4464-71. doi: 10.1016/j.vaccine.2015.07.028. Epub 2015 Jul 22.

18.

Measles in Canada Between 2002 and 2013.

De Serres G, Desai S, Shane A, Hiebert J, Ouakki M, Severini A.

Open Forum Infect Dis. 2015 Apr 15;2(2):ofv048. doi: 10.1093/ofid/ofv048. eCollection 2015 Apr.

19.

The effect of a booster dose of quadrivalent or bivalent HPV vaccine when administered to girls previously vaccinated with two doses of quadrivalent HPV vaccine.

Gilca V, Sauvageau C, Boulianne N, De Serres G, Crajden M, Ouakki M, Trevisan A, Dionne M.

Hum Vaccin Immunother. 2015;11(3):732-8. doi: 10.1080/21645515.2015.1011570.

20.

Immunogenicity of quadrivalent HPV and combined hepatitis A and B vaccine when co-administered or administered one month apart to 9-10 year-old girls according to 0-6 month schedule.

Gilca V, Sauvageau C, Boulianne N, De Serres G, Couillard M, Krajden M, Ouakki M, Murphy D, Trevisan A, Dionne M.

Hum Vaccin Immunother. 2014;10(8):2438-45. doi: 10.4161/hv.29617.

21.

Risk of narcolepsy associated with inactivated adjuvanted (AS03) A/H1N1 (2009) pandemic influenza vaccine in Quebec.

Montplaisir J, Petit D, Quinn MJ, Ouakki M, Deceuninck G, Desautels A, Mignot E, De Wals P.

PLoS One. 2014 Sep 29;9(9):e108489. doi: 10.1371/journal.pone.0108489. eCollection 2014.

22.

Human metapneumovirus viral load is an important risk factor for disease severity in young children.

Roussy JF, Carbonneau J, Ouakki M, Papenburg J, Hamelin MÈ, De Serres G, Boivin G.

J Clin Virol. 2014 Jun;60(2):133-40. doi: 10.1016/j.jcv.2014.03.001. Epub 2014 Mar 12.

PMID:
24686044
23.

Measles in children vaccinated with 2 doses of MMR.

Defay F, De Serres G, Skowronski DM, Boulianne N, Ouakki M, Landry M, Brousseau N, Ward BJ.

Pediatrics. 2013 Nov;132(5):e1126-33. doi: 10.1542/peds.2012-3975. Epub 2013 Oct 21.

PMID:
24144708
24.

Increased risk of anaphylaxis following administration of 2009 AS03-adjuvanted monovalent pandemic A/H1N1 (H1N1pdm09) vaccine.

Rouleau I, De Serres G, Drolet JP, Skowronski DM, Ouakki M, Toth E, Landry M, Ménard S, Gagnon R.

Vaccine. 2013 Dec 5;31(50):5989-96. doi: 10.1016/j.vaccine.2013.10.033. Epub 2013 Oct 19.

PMID:
24144473
25.

Long-term persistence of immunity after vaccination of pre-adolescents with low doses of a recombinant hepatitis B vaccine.

Gilca V, De Serres G, Boulianne N, Murphy D, Ouakki M, De Wals P, Trudeau G, Massé R, Dionne M.

Hum Vaccin Immunother. 2013 Aug;9(8):1685-90. doi: 10.4161/hv.25015. Epub 2013 Jun 6.

26.

Antibody persistence and the effect of a booster dose given 5, 10 or 15 years after vaccinating preadolescents with a recombinant hepatitis B vaccine.

Gilca V, De Serres G, Boulianne N, Murphy D, De Wals P, Ouakki M, Trudeau G, Massé R, Dionne M.

Vaccine. 2013 Jan 7;31(3):448-51. doi: 10.1016/j.vaccine.2012.11.037. Epub 2012 Dec 1.

PMID:
23206974
27.

Egg-allergic patients can be safely vaccinated against influenza.

Des Roches A, Paradis L, Gagnon R, Lemire C, Bégin P, Carr S, Chan ES, Paradis J, Frenette L, Ouakki M, Benoît M, De Serres G; PCIRN (Public Health Agency of Canada/Canadian Institutes of Health Research Influenza Research Network).

J Allergy Clin Immunol. 2012 Nov;130(5):1213-1216.e1. doi: 10.1016/j.jaci.2012.07.046. Epub 2012 Sep 27. Review. No abstract available.

28.

Short and long-term safety of the 2009 AS03-adjuvanted pandemic vaccine.

De Serres G, Gariépy MC, Coleman B, Rouleau I, McNeil S, Benoît M, McGeer A, Ambrose A, Needham J, Bergeron C, Grenier C, Sleigh K, Kallos A, Ouakki M, Ouhoummane N, Stiver G, Valiquette L, McCarthy A, Bettinger J; PHAC-CIHR influenza Research Network (PCIRN).

PLoS One. 2012;7(7):e38563. doi: 10.1371/journal.pone.0038563. Epub 2012 Jul 3.

29.

Seroconversion to seasonal influenza viruses after A(H1N1)pdm09 virus infection, Quebec, Canada.

Baz M, Papenburg J, Hamelin ME, Ouakki M, Skowronski DM, De Serres G, Boivin G.

Emerg Infect Dis. 2012 Jul;18(7):1132-4. doi: 10.3201/eid1807.111680.

30.

Clinicians' opinions on new vaccination programs implementation.

Dubé E, Gilca V, Sauvageau C, Bettinger JA, Boucher FD, McNeil S, Gemmill I, Lavoie F, Ouakki M, Boulianne N.

Vaccine. 2012 Jun 29;30(31):4632-7. doi: 10.1016/j.vaccine.2012.04.100. Epub 2012 May 11.

PMID:
22580354
31.

Comparison of risk factors for human metapneumovirus and respiratory syncytial virus disease severity in young children.

Papenburg J, Hamelin MÈ, Ouhoummane N, Carbonneau J, Ouakki M, Raymond F, Robitaille L, Corbeil J, Caouette G, Frenette L, De Serres G, Boivin G.

J Infect Dis. 2012 Jul 15;206(2):178-89. doi: 10.1093/infdis/jis333. Epub 2012 May 2.

PMID:
22551815
32.

Higher risk of measles when the first dose of a 2-dose schedule of measles vaccine is given at 12-14 months versus 15 months of age.

De Serres G, Boulianne N, Defay F, Brousseau N, Benoît M, Lacoursière S, Guillemette F, Soto J, Ouakki M, Ward BJ, Skowronski DM.

Clin Infect Dis. 2012 Aug;55(3):394-402. doi: 10.1093/cid/cis439. Epub 2012 Apr 27.

PMID:
22543023
33.

School absenteeism as an adjunct surveillance indicator: experience during the second wave of the 2009 H1N1 pandemic in Quebec, Canada.

Kom Mogto CA, De Serres G, Douville Fradet M, Lebel G, Toutant S, Gilca R, Ouakki M, Janjua NZ, Skowronski DM.

PLoS One. 2012;7(3):e34084. doi: 10.1371/journal.pone.0034084. Epub 2012 Mar 30.

34.

The number needed to vaccinate to prevent infant pertussis hospitalization and death through parent cocoon immunization.

Skowronski DM, Janjua NZ, Tsafack EP, Ouakki M, Hoang L, De Serres G.

Clin Infect Dis. 2012 Feb 1;54(3):318-27. doi: 10.1093/cid/cir836. Epub 2011 Dec 8.

PMID:
22156850
35.

Antibody persistence and response to 2010-2011 trivalent influenza vaccine one year after a single dose of 2009 AS03-adjuvanted pandemic H1N1 vaccine in children.

Gilca V, De Serres G, Hamelin ME, Boivin G, Ouakki M, Boulianne N, Sauvageau C, Dionne M, Gilca R, Skowronski D.

Vaccine. 2011 Dec 9;30(1):35-41. doi: 10.1016/j.vaccine.2011.10.062. Epub 2011 Nov 7.

PMID:
22063386
36.

Comparison of pandemic and seasonal influenza in the pediatric emergency department.

Aguirre E, Papenburg J, Ouakki M, Fontela PS, Guimont C, De Serres G, Boivin G.

Pediatr Infect Dis J. 2011 Aug;30(8):633-9. doi: 10.1097/INF.0b013e3182103d54.

PMID:
21289529
37.

Burden of acute otitis media on Canadian families.

Dubé E, De Wals P, Gilca V, Boulianne N, Ouakki M, Lavoie F, Bradet R.

Can Fam Physician. 2011 Jan;57(1):60-5.

38.

Evaluation of serological diagnostic methods for the 2009 pandemic influenza A (H1N1) virus.

Papenburg J, Baz M, Hamelin MÈ, Rhéaume C, Carbonneau J, Ouakki M, Rouleau I, De Serres G, Boivin G.

Clin Vaccine Immunol. 2011 Mar;18(3):520-2. doi: 10.1128/CVI.00449-10. Epub 2011 Jan 12.

39.

Feasibility and impact of providing feedback to vaccinating medical clinics: evaluating a public health intervention.

Brousseau N, Sauvageau C, Ouakki M, Audet D, Kiely M, Couture C, Paré A, Deceuninck G.

BMC Public Health. 2010 Dec 3;10:750. doi: 10.1186/1471-2458-10-750.

40.

Household transmission of the 2009 pandemic A/H1N1 influenza virus: elevated laboratory‐confirmed secondary attack rates and evidence of asymptomatic infections.

Papenburg J, Baz M, Hamelin MÈ, Rhéaume C, Carbonneau J, Ouakki M, Rouleau I, Hardy I, Skowronski D, Roger M, Charest H, De Serres G, Boivin G.

Clin Infect Dis. 2010 Nov 1;51(9):1033-41. doi: 10.1086/656582.

PMID:
20887206
41.

Quality of life of children and their caregivers during an AOM episode: development and use of a telephone questionnaire.

Dubé E, De Wals P, Ouakki M.

Health Qual Life Outcomes. 2010 Jul 26;8:75. doi: 10.1186/1477-7525-8-75.

42.

Safe vaccination of patients with egg allergy with an adjuvanted pandemic H1N1 vaccine.

Gagnon R, Primeau MN, Des Roches A, Lemire C, Kagan R, Carr S, Ouakki M, Benoît M, De Serres G; PHAC-CIHR Influenza Research Network.

J Allergy Clin Immunol. 2010 Aug;126(2):317-23. doi: 10.1016/j.jaci.2010.05.037. Epub 2010 Jun 25.

PMID:
20579720
43.

Canadian family physicians' and paediatricians' knowledge, attitudes and practices regarding A(H1N1) pandemic vaccine.

Dubé E, Gilca V, Sauvageau C, Boulianne N, Boucher FD, Bettinger JA, McNeil S, Gemmill I, Lavoie F, Ouakki M.

BMC Res Notes. 2010 Apr 14;3:102. doi: 10.1186/1756-0500-3-102.

44.

Uptake of pneumococcal conjugate vaccine: methodological issues in measurement and impact of publicly funded programs.

De Wals P, Boulianne N, Sévin E, Ouakki M, Deceuninck G, Guay M.

Can J Public Health. 2009 Nov-Dec;100(6):413-6.

PMID:
20209732
45.

Adult immunization services: steps have to be done.

Huot C, Sauvageau C, Tremblay G, Dubé E, Ouakki M.

Vaccine. 2010 Feb 3;28(5):1177-80. doi: 10.1016/j.vaccine.2009.11.038. Epub 2009 Nov 27.

PMID:
19945413
46.

Reduced physician claims for otitis media after implementation of pneumococcal conjugate vaccine program in the province of Quebec, Canada.

Wals PD, Carbon M, Sévin E, Deceuninck G, Ouakki M.

Pediatr Infect Dis J. 2009 Sep;28(9):e271-5. doi: 10.1097/INF.0b013e3181bad212.

PMID:
19710582
47.

Analysis of mortality following a mass immunization campaign with serogroup C meningococcal conjugate vaccine: methodological difficulties and imperfect solutions.

De Wals P, Deceuninck G, Ouakki M, Boulianne N, De Serres G, Danzig L.

Vaccine. 2009 May 21;27(24):3223-7. doi: 10.1016/j.vaccine.2009.02.055. Epub 2009 Feb 24.

PMID:
19446195
48.

New vaccines offering a larger spectrum of protection against acute otitis media: will parents be willing to have their children immunized?

Dubé E, De Wals P, Gilca V, Boulianne N, Ouakki M, Lavoie F, Bradet R.

Int J Pediatr Otorhinolaryngol. 2009 Jul;73(7):987-91. doi: 10.1016/j.ijporl.2009.03.022. Epub 2009 May 6.

PMID:
19423171
49.

Bats in the bedroom, bats in the belfry: reanalysis of the rationale for rabies postexposure prophylaxis.

De Serres G, Skowronski DM, Mimault P, Ouakki M, Maranda-Aubut R, Duval B.

Clin Infect Dis. 2009 Jun 1;48(11):1493-9. doi: 10.1086/598998.

PMID:
19400689
50.

Attitudes of nurses toward current and proposed vaccines for public programs: a questionnaire survey.

Gilca V, Boulianne N, Dubé E, Sauvageau C, Ouakki M.

Int J Nurs Stud. 2009 Sep;46(9):1219-35. doi: 10.1016/j.ijnurstu.2009.02.013. Epub 2009 Apr 5.

PMID:
19349047

Supplemental Content

Loading ...
Support Center